As Biotechnology companies, Osiris Therapeutics Inc. (NASDAQ:OSIR) and Replimune Group Inc. (NASDAQ:REPL) are our subject to compare. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Osiris Therapeutics Inc.	142.82M	4.59	36.53M	0.30	55.69
Replimune Group Inc.	N/A	0.00	31.03M	-0.99	0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Osiris Therapeutics Inc. and Replimune Group Inc.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Osiris Therapeutics Inc. and Replimune Group Inc.

	Net Margins	Return on Equity	Return on Assets
Osiris Therapeutics Inc.	25.58%	15%	7.8%
Replimune Group Inc.	0.00%	-54.8%	-28.8%

Liquidity

2.2 and 1.9 are the respective Current Ratio and a Quick Ratio of Osiris Therapeutics Inc. Its rival Replimune Group Inc.’s Current and Quick Ratios are 38.1 and 38.1 respectively. Replimune Group Inc. has a better chance of clearing its pay short and long-term debts than Osiris Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors owned 25.3% of Osiris Therapeutics Inc. shares and 56.8% of Replimune Group Inc. shares. About 52.1% of Osiris Therapeutics Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.3% of Replimune Group Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Osiris Therapeutics Inc.	-1.46%	14.94%	41.08%	73.29%	99.18%	25.41%
Replimune Group Inc.	0.69%	7.68%	-13.07%	-36.51%	0%	30.4%

For the past year Osiris Therapeutics Inc. was less bullish than Replimune Group Inc.

Summary

Osiris Therapeutics Inc. beats Replimune Group Inc. on 8 of the 10 factors.

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.